What is de novo lipogenesis?
De novo lipogenesis is the biochemical pathway by which cells synthesise fatty acids from non-lipid precursors such as acetyl-CoA, and it is studied in hepatic, cardiac and metabolic research models.
De novo lipogenesis (DNL) is the metabolic pathway by which a cell builds fatty acids from non-lipid carbon precursors, principally acetyl-CoA derived from carbohydrate and amino acid catabolism, rather than obtaining them from dietary or circulating lipids. It is also referred to in the literature as de novo fatty acid synthesis. The pathway is an enzymatic cascade rather than a receptor or a single gene product, and it terminates in the production of palmitate, a 16-carbon saturated fatty acid, which can then be elongated and desaturated into other species. In the research literature the pathway is most often indexed by the activity or expression of its rate-limiting enzyme, fatty acid synthase (FASN), together with upstream components such as acetyl-CoA carboxylase.
The work described in the evidence below centres on the hepatic and myocardial contexts of this pathway, and on the relationship between DNL flux and lipid accumulation in tissue.
Research Studies
De novo lipogenesis and hepatic lipid accumulation in pre-diabetes
Non-alcoholic fatty liver disease (NAFLD) is defined as excessive accumulation of lipids within hepatocytes in the absence of significant alcohol consumption or other causes of chronic liver disease, and it affects 25% to 30% of the global population and nearly one third of the population in North America [1]. Patients typically present with hepatic steatosis on imaging, elevated liver enzymes, and clinical features of insulin resistance, including pre-diabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidemia and visceral obesity [1]. The minimum criterion for a histologic diagnosis of NAFLD is greater than 5 percent lipid content within hepatocytes [1]. A registered study, Diet Impact on Hepatic Transcriptomics and Lipidomics in Pre-diabetes, examines hepatic transcriptomic and lipidomic responses to diet in this population [1].
FASN and ceramide accumulation in arrhythmogenic cardiomyopathy
Arrhythmogenic cardiomyopathy (ACM) is a heritable disease caused by desmosomal gene mutations and marked by progressive myocardial loss and fibrofatty replacement [2]. In that work, FASN, the rate-limiting enzyme of de novo lipogenesis, was reported to be upregulated in cardiomyocytes of ACM patients and of a corresponding model [2]. The reported finding links FASN-mediated de novo lipogenesis to ceramide accumulation and myocardial damage in this disease context [2]. This is a disease-specific observation in a heritable cardiomyopathy population and should not be generalised to other tissues or to healthy individuals.
Model systems used to study de novo lipogenesis
The evidence available here covers two distinct settings: a clinical research study in a pre-diabetic human population with hepatic endpoints [1], and a mechanistic study in ACM patient cardiomyocytes and an associated model [2]. The two differ in tissue, disease context and the direction of the reported effect, and results from one should not be read across to the other.
| Context | Tissue / population | Reported observation | Source |
|---|---|---|---|
| Pre-diabetes and NAFLD | Human, hepatic; global and North American prevalence figures cited | Hepatic steatosis defined as >5% lipid content in hepatocytes; transcriptomic and lipidomic diet study registered | [1] |
| Arrhythmogenic cardiomyopathy | Human ACM patient cardiomyocytes and a corresponding model | FASN upregulated; FASN-mediated DNL reported to promote ceramide accumulation and myocardial damage | [2] |
Enzymatic identity of the pathway
De novo lipogenesis is not a receptor family. It is a cytosolic enzymatic sequence, and FASN is described in the evidence as its rate-limiting enzyme [2]. This matters for how the literature is read: measurements of FASN expression are used as a proxy for pathway activity, and upregulation of FASN in a tissue is reported as evidence of increased de novo lipogenesis in that tissue [2].
Where the evidence is animal-only or in vitro
The ACM findings are reported in patient cardiomyocytes and in a model system rather than in a controlled human intervention [2]. The pre-diabetes material is a registered clinical study protocol with prevalence and diagnostic-criterion data, not an interventional result [1]. No human dose, treatment protocol or clinical outcome is established by either source.
What the pathway is not
De novo lipogenesis is distinct from dietary fat absorption and from lipolysis of stored triglyceride. The evidence here does not support claims about weight, body composition, or any clinical endpoint in humans, and no such claim is made on this page.
If you are reading this for personal health reasons
The materials discussed on this page are sold for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.